{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:23Z","timestamp":1791497603969,"version":"4.3.4"},"reference-count":87,"publisher":"Ubiquity Press, Ltd.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["gh"],"DOI":"10.5334\/gh.1154","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T05:29:09Z","timestamp":1665725349000},"page":"75","source":"Crossref","is-referenced-by-count":128,"title":["World Heart Federation Cholesterol Roadmap 2022"],"prefix":"10.5334","volume":"17","author":[{"given":"Kausik K.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Ference","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"S\u00e9verin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko H.","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Almahmeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Daccord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Ezhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Fern\u00e1ndez","family":"Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Gidding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lloyd-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Perel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3285","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"25","key":"key20221014052900_B1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study","volume":"76","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"key20221014052900_B2","year":"2022"},{"key":"key20221014052900_B3","article-title":"The collateral damage of COVID-19 to cardiovascular services: A meta-analysis","year":"2022","journal-title":"European Heart Journal"},{"issue":"10331","key":"key20221014052900_B4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S0140-6736(21)02347-3","article-title":"NCD Countdown 2030: Efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"key20221014052900_B5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.gheart.2017.03.002","article-title":"World Heart Federation Cholesterol Roadmap","volume":"12","year":"2017","journal-title":"Glob Heart"},{"issue":"1","key":"key20221014052900_B6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ije\/dyz099","article-title":"National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: A pooled analysis of 458 population-based studies in Asian and Western countries","volume":"49","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"18","key":"key20221014052900_B7","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","year":"2009","journal-title":"Jama"},{"issue":"7810","key":"key20221014052900_B8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","article-title":"Repositioning of the global epicentre of non-optimal cholesterol","volume":"582","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2020","journal-title":"Nature"},{"issue":"1","key":"key20221014052900_B9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2015.04.810","article-title":"Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary","volume":"241","year":"2015","journal-title":"Atherosclerosis"},{"issue":"3","key":"key20221014052900_B10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content","volume":"7","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"10349","key":"key20221014052900_B11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"key20221014052900_B12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"290","author":"ESC Committee for Practice Guidelines (CPG), Societies ENC","year":"2019","journal-title":"Atherosclerosis"},{"key":"key20221014052900_B13","first-page":"n776","article-title":"Role of coronary artery calcium score in the primary prevention of cardiovascular disease","volume":"373","year":"2021","journal-title":"BMJ"},{"issue":"19","key":"key20221014052900_B14","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","year":"2013","journal-title":"Jama"},{"issue":"5","key":"key20221014052900_B15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and\/or Hypertriglyceridemia","volume":"5","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"key20221014052900_B16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.117.030677","article-title":"Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy","volume":"137","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"key20221014052900_B17","article-title":"Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels","volume":"4","year":"2021","journal-title":"JAMA Netw Open"},{"key":"key20221014052900_B18","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society Consensus Statement","year":"2022"},{"issue":"20","key":"key20221014052900_B19","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa2109191","article-title":"Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"key20221014052900_B20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/CIRCULATIONAHA.115.018585","article-title":"Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review","volume":"133","year":"2016","journal-title":"Circulation"},{"issue":"10338","key":"key20221014052900_B21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","article-title":"Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"key20221014052900_B22","article-title":"Reduction in saturated fat intake for cardiovascular disease","volume":"5","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"key20221014052900_B23","first-page":"S5","article-title":"Health effects of trans-fatty acids: experimental and observational evidence","volume":"63","year":"2009","journal-title":"Eur J Clin Nutr"},{"issue":"23","key":"key20221014052900_B24","first-page":"e472","article-title":"2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association","volume":"144","year":"2021","journal-title":"Circulation"},{"issue":"34","key":"key20221014052900_B25","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","journal-title":"Eur Heart J"},{"issue":"24","key":"key20221014052900_B26","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"key20221014052900_B27","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","article-title":"World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions","volume":"7","author":"WHO CVD Risk Chart Working Group","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"12","key":"key20221014052900_B28","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamacardio.2017.4191","article-title":"Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis","volume":"2","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"1","key":"key20221014052900_B29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"issue":"17","key":"key20221014052900_B30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1161\/CIRCULATIONAHA.121.057889","article-title":"Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study","volume":"145","year":"2022","journal-title":"Circulation"},{"issue":"30","key":"key20221014052900_B31","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/eurheartj\/ehac009","article-title":"PDAY risk score predicts cardiovascular events in young adults: the CARDIA study","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"issue":"14","key":"key20221014052900_B32","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease","volume":"322","year":"2019","journal-title":"JAMA"},{"issue":"25","key":"key20221014052900_B33","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key20221014052900_B34","first-page":"i721","article-title":"Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study","volume":"352","year":"2016","journal-title":"BMJ"},{"issue":"Suppl 2","key":"key20221014052900_B35","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/heartjnl-2014-305693","article-title":"Joint British Societies\u2019 consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","author":"JBS3 Board","year":"2014","journal-title":"Heart"},{"issue":"1","key":"key20221014052900_B36","first-page":"1","article-title":"2016 Chinese guidelines for the management of dyslipidemia in adults","volume":"15","author":"Joint Committee for Guideline Revision","year":"2018","journal-title":"J Geriatr Cardiol"},{"issue":"4","key":"key20221014052900_B37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"key20221014052900_B38","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of Familial Hypercholesterolemia Among the General Population and Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"141","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"key20221014052900_B39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/20786204.2011.10874054","article-title":"Familial hypercholesterolemia","volume":"53","year":"2011","journal-title":"South African Family Practice"},{"issue":"10312","key":"key20221014052900_B40","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"398","author":"EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"key20221014052900_B41","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"key20221014052900_B42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2021.03.042","article-title":"A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia","volume":"325","year":"2021","journal-title":"Atherosclerosis"},{"issue":"10","key":"key20221014052900_B43","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: A consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10326","key":"key20221014052900_B44","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: Retrospective cohort study","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"key20221014052900_B45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","year":"2006","journal-title":"Jama"},{"key":"key20221014052900_B46","article-title":"Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"19","key":"key20221014052900_B47","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population","volume":"134","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"key20221014052900_B48","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study","volume":"28","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"key20221014052900_B49","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","year":"2022","journal-title":"European Heart Journal"},{"issue":"25","key":"key20221014052900_B50","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"key20221014052900_B51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.gheart.2015.04.006","article-title":"Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap","volume":"10","year":"2015","journal-title":"Glob Heart"},{"issue":"32","key":"key20221014052900_B52","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"issue":"10","key":"key20221014052900_B53","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia","volume":"5","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"Supplement 1","key":"key20221014052900_B54","article-title":"Statin induced myalgia on high intensity statin in patients with Acute Coronary Syndrome","volume":"42","year":"2021","journal-title":"European Heart Journal"},{"issue":"27","key":"key20221014052900_B55","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence \u2013 Focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","year":"2018","journal-title":"Eur Heart J"},{"key":"key20221014052900_B56","article-title":"Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials","year":"2022","journal-title":"J Clin Lipidol"},{"key":"key20221014052900_B57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","year":"2019","journal-title":"Atherosclerosis"},{"key":"key20221014052900_B58","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","year":"2008","journal-title":"BMJ"},{"issue":"11","key":"key20221014052900_B59","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up","volume":"67","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"key20221014052900_B60","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jacc.2021.09.004","article-title":"Familial Hypercholesterolemia: JACC Focus Seminar 4\/4","volume":"78","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9965","key":"key20221014052900_B61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial","volume":"385","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"key20221014052900_B62","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-Term Evolocumab in Patients With Familial Hypercholesterolemia","volume":"75","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"key20221014052900_B63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"key20221014052900_B64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"key20221014052900_B65","article-title":"Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"key20221014052900_B66","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"44","key":"key20221014052900_B67","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"key20221014052900_B68","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/S2214-109X(21)00551-9","article-title":"Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: A cross-sectional study of nationally representative, individual-level data","volume":"10","year":"2022","journal-title":"Lancet Glob Health"},{"key":"key20221014052900_B69","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2018.05.047","article-title":"Universal screening at age 1\u20132 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis","volume":"275","year":"2018","journal-title":"Atherosclerosis"},{"issue":"17","key":"key20221014052900_B70","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","article-title":"Child-Parent Familial Hypercholesterolemia Screening in Primary Care","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"key20221014052900_B71","article-title":"Screening in children for familial hypercholesterolaemia: start now","year":"2022","journal-title":"Eur Heart J"},{"key":"key20221014052900_B72","unstructured":"FH Europe. FH Europe Post-technical meeting: Statement on FH Paediatric Screening 2021 [cited 2022 13 June]. Available from: https:\/\/fheurope.org\/latest-news\/post-technical-meeting-statement-on-fh-paediatric-screening\/."},{"issue":"2","key":"key20221014052900_B73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action","volume":"5","author":"Representatives of the Global Familial Hypercholesterolemia Community","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"6","key":"key20221014052900_B74","article-title":"Healthcare worker-based opportunistic screening for familial hypercholesterolemia in a low-resource setting","volume":"17","year":"2022","journal-title":"PLoS One"},{"key":"key20221014052900_B75","author":"World Heart Federation","year":"2021"},{"issue":"8","key":"key20221014052900_B76","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"issue":"34","key":"key20221014052900_B77","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"key20221014052900_B78","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12961-020-00588-8","article-title":"Individual, health system, and contextual barriers and facilitators for the implementation of clinical practice guidelines: A systematic metareview","volume":"18","year":"2020","journal-title":"Health Res Policy Syst"},{"issue":"3","key":"key20221014052900_B79","article-title":"Barriers and Strategies in Guideline Implementation-A Scoping Review","volume":"4","year":"2016","journal-title":"Healthcare (Basel)"},{"key":"key20221014052900_B80","author":"NCD Alliance","year":"2019"},{"issue":"34","key":"key20221014052900_B81","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice \u2013 Supplementary Data","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"key20221014052900_B82","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMe1611081","article-title":"What Should Be the Screening Strategy for Familial Hypercholesterolemia?","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"key20221014052900_B83","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20221014052900_B84","first-page":"43","article-title":"Association of copayment with likelihood and level of adherence in new users of statins: A retrospective cohort study","volume":"20","year":"2014","journal-title":"J Manag Care Pharm"},{"issue":"10306","key":"key20221014052900_B85","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis","volume":"398","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"key20221014052900_B86","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2013.08.1665","article-title":"Polypills: Essential medicines for cardiovascular disease secondary prevention?","volume":"63","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9841","key":"key20221014052900_B87","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"}],"container-title":["Global Heart"],"original-title":[],"link":[{"URL":"https:\/\/storage.googleapis.com\/jnl-up-j-gh-files\/journals\/1\/articles\/1154\/submission\/proof\/1154-1-5295-1-10-20221014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:51:54Z","timestamp":1761551514000},"score":1,"resource":{"primary":{"URL":"https:\/\/globalheartjournal.com\/article\/10.5334\/gh.1154\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,11]]}},"URL":"https:\/\/doi.org\/10.5334\/gh.1154","relation":{},"ISSN":["2211-8179","2211-8160"],"issn-type":[{"value":"2211-8179","type":"electronic"},{"value":"2211-8160","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}